He currently serves on the Research Executive Committee of the Canadian Consortium of Neurodegeneration and Aging funded by the Canadian Institutes of Health Research and is Director of the Alzheimer Disease Cooperative Study
funded through the National Institute on Aging.
Compared with a pooled, placebo-arm cohort study conducted by the Alzheimer Disease Cooperative Study
Group over a period of 12 months, ANAVEX 2-73 would have been associated with a 1.8-point bump in score on the MMSE (P less than.016) and a 4-point benefit on the ADCS-ADL (P less than.019).
However, recent findings from the Alzheimer Disease Cooperative Study
found that a regimen of high-dose B vitamins (folate, B6 and B12) did not slow the cognitive decline in people with mild to moderate Alzheimer's disease.